Introduction
The composition of the normal human gastrointestinal microflora is stable within the individual. This indigenous flora protects against colonisation of potentially pathogenic microorganisms. Antimicrobial agents which are excreted from the salivary glands, bile, gastric mucosa or are incompletely absorbed, are known to affect the normal oropharyngeal and gastrointestinal microflora. A disturbance in the ecological balance can reduce the colonisation resistance and subsequently let potentially pathogenic microorganisms invade the intestines with overgrowth and emergence of resistant microorganisms, which may lead to serious infections and treatment failures (Nord & Edlund, 1991) . Oral administration of amoxycillin has previously been shown to cause moderate ecological disturbances in the oral and intestinal tract with overgrowth C. A. Stark ex al.
of amoxycillin-resistant enterobacteria (Lacey et al., 1983; Norrby, 1986; Brismar, Edlund & Nord, 1993) .
In the stomach the production of acid leads to a rapid decrease in the number of luminal microorganisms whereas the mucosa harbours a large number of microorganisms, protected by the mucus layer. The microorganisms usually found here are streptococci, micrococci, staphylococci and veillonella, all belonging to the normal microflora (Sjostedt et al., 1989) . Helkobacter pylori can be found strictly associated with the surface of the gastric mucosa. The presence of H. pylori is clearly associated with gastritis and peptic ulcer disease. Successful eradication of H. pylori is known to heal active gastritis rapidly and cure associated peptic ulcer disease. One of the more recent treatment regimens against H. pv/on-associated duodenal and gastric ulcers includes a proton pump inhibitor, omeprazole, with profound acid inhibitory capacity, and amoxycillin. A combination of omeprazole and amoxycillin has been shown to eradicate H. pylori in 37-80% of duodenal ulcer patients (Gad & Unge, 1994; National Institute of Health, 1994; Walsh & Peterson, 1995) . However, very little is known how such a combination therapy affects the gastrointestinal microflora.
In the present study, the ecological effects on the oral and gastrointestinal microflora after administration of omeprazole 20 mg with amoxycillin 1000 mg bd or omeprazole 20 mg with placebo bd for 2 weeks were compared. The presence of H. pylori in saliva, dental plaque, faecal samples and gastric biopsies was determined by culture and for gastric biopsies also with the polymerase chain reaction (PCR).
Material and methods

Subjects and drug administration
From June 1994 to February 1995, 28 patients referred for upper endoscopy at the Department of Surgery and Gastroenterology, Huddinge University Hospital, participated in the study. The patients gave informed consent and the study was approved by the Local Ethics Committee of Huddinge University Hospital, Karolinska Institute, Stockholm, Sweden. Patients that were positive for H. pylori by the rapid urease test (CLO, Delta West, Australia), later confirmed by either culture, histology or PCR, were included in the study. Patients who had received omeprazole, antacids or antimicrobial agents during the last month were excluded. Patients with allergy to penicillins, underlying disease such as heart or renal failure, cancer, or age below 18 years were also excluded. Fourteen patients were given 20 mg omeprazole capsules (Losec, Astra, Sweden) bd plus amoxycillin (Amoxicillin Scand Pharm, Scand Pharm, Sweden) capsules 1,000 mg bd for two weeks and 14 patients were given omeprazole capsules 20 mg plus placebo (Apoteksbolaget, Sweden) capsules bd for 2 weeks. The omeprazole-amoxycillin group consisted of eight men and six women (mean age 55.1 years, range 22-78). Seven patients had peptic ulcer disease and seven patients had dyspepsia without active ulceration. The omeprazole-placebo group consisted of seven men and seven women (mean age 58.6 years, range 26-81). Eight patients had peptic ulcer disease and six patients had dyspepsia without active ulceration. There were no statistical differences between the two groups concerning age, sex or endoscopic diagnosis. The two treatment groups were randomized in a double blind fashion. The patients returned to the endoscopy ward on treatment day 10 and 4 weeks after treatment (day 42) for endoscopy and bacteriological sampling. During the follow-up period the patients were not permitted to take any acid suppressive agents, antacids or any antimicrobial agents.
Sample procedures
Saliva, dental plaque, biopsies from the gastric mucosa, and faecal samples were collected into sterile plastic containers before the onset of the treatment, day 0, on day 10 and on day 42. Saliva and dental plaque were collected before the gastroscopy in order not to contaminate saliva with the gastric microflora.
Biopsies from antrum and corpus were placed in 1 mL BHI (Brain Heart Infusion) broth. All samples were immediately frozen at -70°C until processed.
Processing of samples for microbiological studies
Saliva and faecal samples were suspended in prereduced peptone yeast glucose medium, diluted tenfold to 10 " 7 and inoculated on selective agar as described by Heimdahl & Nord (1979) . The biopsies were thawed at room temperature, weighed (mean weight for biopsies from the omeprazole-amoxycillin group: 0.014 g (S.D. 0.007), and from the omeprazole-placebo group: 0.012 g (S.D. 0.007), homogenized, diluted ten-fold to 10 ~5 in prereduced peptone yeast glucose medium, and inoculated on selective media as described by Sjostedt et al. (1989) . The limit of detection for saliva and faeces was 10 2 cfu/mL or cfu/g and for gastric biopsies 10 3 cfu/g. The aerobic agar plates were incubated for 24 h at 37°C and anaerobic plates were incubated for 48 h at 37°C in anaerobic jars (Gas Pak, BBL, MD, USA). After incubation different colony types were counted, isolated in pure culture and identified to genus level by morphological, biochemical and gas-chromatographic analysis. Differences in numbers of a particular microorganisms of log? or greater were considered to represent a significant change (Nord, 1990) . Numerical values of microorganisms in antrum and corpus were presented as a mean value for the gastric mucosa.
Detection o/H. pylori Saliva, dental plaque, biopsies, and faeces were inoculated undiluted and diluted onto a selective agar: Brucella agar (BBL, MD, U §A) agar, i.e. sheep blood, vancomycin 6 mg/L, nalidixic acid 20 mg/L, amphotericin B 2 mg/L and menadione 1 mg/L in order to detect H. pylori. Plates were incubated at 37°C for 5 days in anaerobic jars with microaerophilic atmosphere suitable for H. pylori (Campy Pak, BBL, MD, USA). Colonies were typed by colony morphology, Gram-staining and biochemical tests.
PCR was used in order to detect the presence of H. pylori in the gastric biopsies. In order to perform the DNA extraction, 10 jiL of the BHI surrounding the homogenized biopsy was placed in 400 //L Chelex-100 (Bio-Rad, CA, USA) and 20 //L proteinase K. (1 mg/mL), incubated at 65°C for 60 min, then boiled for lOmin and centrifuged 15 OOOg for 10 min. The supernatant was then ready to be used for PCR. The PCR mixture consisted of: 27 /iL MilliQ, 2 /it dNTP (dATP, dCTP, dUTP, dGTP) (Perkin Elmer, NJ, USA), 2//L MgCI, 5//L 10 x Buffer (Perkin Elmer, NJ, USA), 0.5/iL Uracil-N-glycosylate (UNG) (Boehringer Mannheim, Germany), 0.25/iL Taq polymerase (Perkin Elmer, NJ, USA), 1 pL primer JW21 and 1 y.L primer JW22 per 100 /iL (Jackson et al., 1990) . The UNG was used to prevent carry-over contamination. A segment of H. pylori 16S rRNA gene was amplified by the used oligonucleotide primers. The reaction mixture was heated to 37°C for 5 min for the UNG to perform, then increased to 95°C for 10 min, and thereafter subjected to 35 cycles (94°C for 30 sec, 55°C for 30 sec and 72°C for 30 sec) and finally 5 min at 72°C. The PCR product was analysed on a 1% agarose gel stained with ethidium bromide. The reference strain was H. pylori NCTC 11637.
One biopsy from antrum and one from corpus for histological examination was fixed in phosphate-buffered formalin (4%, pH 7.4) and stained by standard methods (haematoxylin and eosin, Giemsa). All biopsies were later analysed by one examiner in order to determine the presence of H. pylori (modified Giemsa stain) (Gad, 1988) .
A rapid urease test (CLO) was performed on one biopsy from antrum and one biopsy from corpus in connection with the gastroscopies. A clearly visible colour change within 24 h was considered positive. The results of CLO-tests and histological examinations during the study were known by the endoscopists. For inclusion, at least two of the four above mentioned tests had to be positive. H. pylori was regarded as eradicated when all four tests were negative.
Antibiotic susceptibility tests
The minimum inhibitory concentrations (MICs) of amoxycillin were determined for enterobacteria and enterococci from the faecal samples by the agar dilution method using PDM Antibiotic Sensitivity Medium (AB Biodisk, Sweden). The inoculum was 10 6 cfu/mL and the agar plates were incubated at 37°C for 24 h. Reference strains were Escherichia coli ATCC 25922 and Enterococcus faecalis ATCC 29212. The strains were considered resistant if the MIC was greater than 16mg/L. MIC was defined as the lowest concentration of the drug which inhibited growth completely. MICsow were the concentrations which inhibited the growth of 50% and 90% of the strains tested, respectively.
Determination of the fi-lactamase activity
Saliva was sonicated for 4 x 30 sec in an icebath and centrifuged at 20,000g for 10 min (Branson Sonifier Celldisruptur B15). Faecal samples were diluted 1:4 (w/v) in 50 mM phosphate buffer, pH 7.0 and Triton-X 0.5% at 4 C for 2 h in order to break the cell walls and release both intra-and extracellular enzyme. The faecal samples were centrifuged at 20,000g for 10 min and intra-and extracellular /?-lactamase activities were assayed spectrophotometrically with nitrocefin (Glaxo, Greenford, UK), 100 /.IM, in 50 mM phosphate buffer (pH 7.0, 30°C) as the substrate (O'Callaghan et al., 1972; Stark et al., 1995) . All determinations were done in duplicate. One unit of ^-lactamase (U) was defined as the amount that formed 1.0 /imol of product per minute under these conditions.
Results
Influence of omeprazole and amoxycillin versus omeprazole and placebo on the oral microflora
The aerobic salivary microflora was markedly affected by the administration of omeprazole and amoxycillin (Table I ). The number of Streptococcus milleri increased Median (minimum-maximum) of log values of the number of microorganisms per mL saliva.
•Number of patients with detectable levels of microorganisms within the sampling penod. 'Number of patients with delectable levels of microorganisms at the actual sampling day in five patients during the treatment while Streptococcus salivarius and Streptococcus sanguis were significantly reduced in numbers in nine patients during the treatment. After four weeks, the numbers of streptococci had returned to pretreatment levels. The number of Stomatococcus mucilaginosus decreased while there was an overgrowth of Haemophilus species during the treatment but these microorganisms returned to pretreatment levels on day 42. Enterobacteria were not detected in any of the patients on day 0, but one patient was colonized by Klebsiella oxytoca on day 10, and one patient was colonized by Enterobacter cloacae and Klebsiella pneumoniae on days 10 and 42. The anaerobic microflora was significantly reduced by the treatment with omeprazole and amoxycillin. The numbers of anaerobic Gram-positive cocci, fusobacteria and leptotrichia were reduced but returned to pretreatment levels after four weeks. Administration of omeprazole and placebo did not affect the oral microflora which reflects the stability of the flora (Table I) .
Influence of omeprazole and amoxycillin versus omeprazole and placebo on the gastric mucosal microflora
There was an overgrowth of microorganisms in the stomach during the treatment with omeprazole-amoxycillin (Table II) . The numbers of S. milleri and Streptococcus mitior increased while the numbers of S. salivarius and S. sanguis decreased in numbers during the treatment. Neisseria and haemophilus strains increased in numbers on day 10, but returned to pretreatment levels after four weeks. The patient who harboured E. cloacae and K. pneumoniae in the oral microflora was also colonised by these enterobacteria in the gastric mucosa during the treatment. Two other patients were colonised on day 10 with K. oxytoca and Enterobacter agglomerans respectively. Yeasts were not found in any patient at the start of the study, but in three patients on day 10 and day 42. The number of bacteroides increased during the treatment and returned to pretreatment levels after 4 weeks. The number of actinomyces increased during treatment with remaining high numbers on day 42.
A general increase in the numbers of gastric mucosal microflora was seen in the omeprazole-placebo group during the investigation period (Table II) . Streptococci, micrococci, neisseria and haemophilus increased significantly during the treatment and only neisseria returned to pretreatment levels after 4 weeks. During the omeprazole treatment period, two patients were colonised by E. coli and Pseudomonas species respectively. Two patients were colonised with yeasts throughout the investigation period. Actinomyces, veillonella, bacteroides and fusobacteria increased during treatment but returned to pretreatment levels on day 42.
Influence of omeprazole and amoxycillin versus omeprazole and placebo on the intestinal microflora
In the aerobic intestinal microflora an overgrowth of enterobacteria other than E. coli (E. cloacae, Citrobacter freundii, K. pneumoniae, K. oxytoca and Morganella morganii) was observed during the omeprazole-amoxycillin treatment (Table III) . Yeasts were not detected in any of the patients on day 0, but were present in five patients during the treatment and in three patients after four weeks. Anaerobic Gram-positive cocci and veillonella were significantly reduced in numbers on day 10, and veillonella Omeprazole-amoxycillin cocci were still found in low numbers on day 42. In the omeprazole-placebo group a moderate increase in the number of microorganisms was noted in the intestinal microflora (Table III) . The numbers of enterococci and enterobacteria other than E. coli (Citrobacter diversus, C.freundii, E. agglomerans, E. cloacae and K. pneumoniae) increased on day 10 but returned to pretreatment levels after four weeks. Two patients were colonised with yeasts from the start of the study and another three patients were colonised during the study. In these patients yeasts were still present on day 42. There was a marked increase in the number of anaerobic Gram-positive cocci during the treatment.
Detection ofH. pylori
The concordance of the results from cultivation, histology, PCR and CLO tests were analysed. Two or more positive tests were considered to establish a true infection. Initially, all 14 patients in the omeprazole-amoxycillin group had H. pylori in the gastric mucosa as indicated by at least two positive results of the four tests from antrum, corpus or both. Four of these patients were positive on day 10, and seven patients were positive after 4 weeks, giving an eradication rate of 50%. Thirteen of the 14 patients in the omeprazole-placebo group had H. pylori in the gastric mucosa as indicated by at least two positive results from antrum, corpus or both.
One patient was included in the study with positive CLO test on day 0 and 42, but was negative for H. pylori by culture, histology and PCR throughout the study. The CLO test was regarded as falsely positive in this patient. Eleven patients were positive for H. pylori during the treatment with omeprazole, and 14 patients were positive after 4 weeks. H. pylori was not detected by culture in saliva, dental plaque or faecal samples.
Antibiotic susceptibility tests
All faecal enterococcal and enterobacterial isolates were tested for MIC values of amoxycillin with the agar dilution method (Table IV) . A significant increase in the MICw values was noted during the treatment with omeprazole and amoxycillin. MICww values at day 42 for enterococci and E. coli did not vary significantly from day 0, although MICMSO values for enterobacteria other than E. coli remained increased.
fi-Lactamase activity
Changes in /Mactamase activity were recorded in saliva and faeces from both treatment groups. Detectable levels of /Mactamase in the saliva were found in one patient before the onset of the study, and an increase in /Mactamase production in saliva was seen in three patients during treatment with omeprazole and amoxycillin. In the faecal samples a detectable level was recorded for seven patients on day 0 (median value 0.012 U/g, range 0-4.94 U/g), and increased levels were observed on day 10 in ten patients while no decrease in /Mactamase levels was seen in the omeprazole-amoxycillin group (median value 0.082 U/g, range 0-5.76 U/g). Four weeks after cessation of the therapy, eight patients had detectable /Mactamase activity (median value 0.047 U/g, range 0-1.19 U/g). 14 Veillonella spp.
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Bacleroides spp. In the omeprazole-placebo group, no detectable /Mactamase production was recorded for the saliva samples, but for two of the faecal samples on day 0 (0.110 U/g and 0.404 U/g). An increase in intestinal /Mactamase production was seen in three patients, and one patient with a decrease in /Mactamase activity was recorded during or after the treatment in the omeprazole-placebo group.
Discussion
The human gastrointestinal tract harbours a huge potential reservoir of resistant microorganisms which may cause serious infections in other sites of the body. Bacteria from the intestinal microflora dominate as causative agents in post-operative infections, and resistance among them may seriously complicate the prophylaxis and treatment of intraabdominal infections. Several studies have shown a correlation between the consumption of antimicrobial agents and the emergence of bacterial drug resistance in the normal intestinal microflora (Levy et al., 1988; Stark et al., 1993; Shanahan, Thomson & Amyes, 1994) . The results of the present study indicate that treatment with omeprazole in combination with amoxycillin will result in an overgrowth of potentially pathogenic strains in the oral, gastric and intestinal microflora. Even treatment with omeprazole alone may result in an overgrowth of potentially pathogenic microorganisms in the gastric as well as the intestinal microflora. This may have implications in patients on long term omeprazole therapy, e.g. in patients with gastroesophageal reflux disease where treatment may be life-long.
The potential of an antimicrobial agent to disturb the normal microflora is related not only to its in-vitro properties, but also to the route of administration, dose and pharmacokinetic properties. In the present study, observed changes in the numbers of microorganisms in the saliva samples originate solely from the administration of amoxycillin. A parameter of ecological disturbance in the oral microflora noted in the omeprazole-amoxydllin group was the new colonisation of enterobacteria in two patients. Similar results have been observed in other studies (Lacey et al., 1983; Norrby, 1986; Brismar et al., 1993) . The administration of omeprazole alone did not affect the number of oral microorganisms, probably because the parietal cell in the gastric mucosa is the only target of the drug.
In the stomach, ecological disturbances were seen in both treatment groups. The general increase in the total number of microorganisms can be explained by the increased pH caused by omeprazole. Interestingly several groups of microorganisms remained at high levels after cessation of treatment. Intake of omeprazole 20 mg twice daily has been shown to generally increase gastric pH to above 4 approximately 80% of the time, which will enable growth of most bacteria (Sjostedt et al., 1994) . Omeprazole administered in capsules will be absorbed in the small intestine and is activated within the acidic environment in the parietal cells where it has its specific activity (Maton, 1991) . Omeprazole has an effect on H. pylori in vitro, but it is not known whether omeprazole has any effect on the normal microflora in vitro (Nakao et al., 1995) .
When omeprazole was administered together with amoxycillin, the increase in the number of microorganisms in the gastric mucosa was much less pronounced, although overgrowth of enterobacteria and yeasts in the stomach appeared. As seen in the oral microflora, the numbers of S. salivarius and S. sanguis were decreased in this compartment as well. The number of bacteroides increased in the gastric mucosa but not in saliva or faeces. /?-Lactamase producing bacteroides strains often have MIGw-values exceeding 256 mg/L for amoxycillin and the growth of these microorganisms are also probably favoured by the increased pH.
The increase in gastric pH following omeprazole therapy seems to affect the number of intestinal microorganisms, as shown in the present study. The lower gastric acidity will subsequently increase the number of microorganisms in the stomach and may affect the number of microorganisms leaving the stomach for the intestines. In the present study, a selection of amoxycillin resistant E. coli and an overgrowth of amoxycillin resistant enterobacteria other than E. coli was observed in the amoxycillin group during the study, findings which are in accordance with studies by Norrby (1986) and Brismar el al. (1993) . The MIC M and MIC90 values for enterococci, E. coli and other enterobacteria isolated from faecal samples of the omeprazole-amoxycillin group increased significantly during treatment. Multiresistant enterococci are an increasing problem in nosocomial infections, and the risk of selection of these constitutively /Mactamase producing strains must not be neglected. A general opinion is that since resistance to /?-lactam antibiotics increases among clinical isolates of Gram-negative aerobic bacteria, continued surveillance of patients medicating with omeprazole in combination with antimicrobial agents will be required before the risks of this therapy can be estimated (Maton, 1991) . Induction of /J-lactamase producing strains may seriously complicate the treatment of infectious diseases. On the other hand, enzymatic inactivation of the drug in the intestines may be an ecological advantage and may decrease the disturbances of the antimicrobial agent on the normal intestinal microflora (Chacaty et al., 1993; Edlund, Stark & Nord, 1994; Stark et al., 1995) . The basal level of /?-lactamase production and the increase in /?-lactamase activity in the faecal samples during the treatment observed in the omeprazole-amoxycillin group may act as a protector for more serious ecological adverse effects. The faecal samples of the omeprazole-placebo group had a lower basal level of /?-lactamase (day 0), and no increase was observed during treatment.
The eradication rate of H. pylori 4 weeks after cessation of the combination therapy was 50% in the present study, which is within the range of results from previous studies (Walsh & Peterson, 1995) .
The results of the present investigation show that treatment with omeprazole 20 mg in combination with amoxycillin 1000 mg twice daily for 14 days alters the normal microflora in the oral, gastric and intestinal tract and permits antibiotic resistant bacteria and potentially pathogenic microorganisms to increase in numbers in the intestinal microflora. Even omeprazole 20 mg bd as single therapy for 14 days results in overgrowth of potentially pathogenic microorganisms both in the gastric and the intestinal microflora. The ecological impact on the normal oral and gastrointestinal microflora should be taken into consideration when omeprazole and antimicrobial agents are used.
